Lilly Threatens to End 340B Discounts for Non-Compliant Hospitals Within Five Days
Eli Lilly issued an ultimatum to hospitals in the 340B Drug Pricing Program, demanding submission of claims data within five days or face termination of discounted drug pricing. The pharmaceutical manufacturer's action targets hospitals that have not complied with its data reporting requirements under the 340B program. This move escalates ongoing tensions between drug manufacturers and 340B-covered entities over transparency and program integrity. The deadline creates immediate operational and financial pressure on affected hospitals that rely on 340B discounts to support uncompensated care and safety-net services.
Medicaid managed care organizations contract with 340B hospitals whose financial stability and pharmacy operations could be disrupted if Lilly follows through, potentially affecting network adequacy and access to pharmaceutical services for Medicaid beneficiaries.
Pharmacy · Managed Care
You might also like